Decreased intestinal acetylcholinesterase in early Parkinson disease: An <sup>11</sup>C-donepezil PET study.

Fedorova, Tatyana D; Seidelin, Louise B; Knudsen, Karoline; Schacht, Anna C; Geday, Jacob; Pavese, Nicola; Brooks, David J; Borghammer, Per · Neurology · 2017

cross_sectional · Level IV

Where this comes from

Abstract

To investigate systemic levels of acetylcholinesterase in early Parkinson disease (PD) with <sup>11</sup>C-donepezil PET, a potential marker of parasympathetic innervation. This was a cross-sectional study with 19 patients with early-stage PD (disease duration 1.5 ± 0.6 years) and 16 age-matched controls who had clinical assessments, olfaction tests, and <sup>11</sup>C-donepezil PET to measure acetylcholinesterase density in peripheral organs. The patients with PD showed significantly reduced <sup>11</sup>C-donepezil uptake in the small intestine (-14%, <i>p</i> = 0.018), colon (-22%, <i>p</i> < 0.001), and kidneys (-14%, <i>p</i> = 0.028). No difference in myocardial or pancreatic acetylcholinesterase levels was seen. We found significantly decreased <sup>11</sup>C-donepezil signal in the intestine and kidneys of patients with early PD, suggesting that parasympathetic denervation is present early in the disease course.

Medical subject headings